Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

References

• Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385–389.
   PubMed Web of Science ®Google Scholar
• Miller JS, Warren EH, van den Brink MR, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/leukemia reaction. Biol Blood Marrow Transplant. 2010;16:565–586.
   PubMed Web of Science ®Google Scholar
• Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373:1550–1561.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443–458.
   PubMed Web of Science ®Google Scholar
• Pasquini M, Wang Z, Horowitz MM, et al. 2013 report from the center for international blood and marrow transplant research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2013;187–197.
   PubMedGoogle Scholar
• Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005;36:757–769.
   PubMed Web of Science ®Google Scholar
• O’Sullivan LA, Liongue C, Lewis RS, et al. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease. Mol Immunol. 2007;44:2497–2506.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368:161–170.
   PubMed Web of Science ®Google Scholar
• Carniti C, Gimondi S, Vendramin A, et al. Pharmacologic inhibition of JAK1/JAK2 signaling reduces experimental murine acute GVHD while preserving GVT effects. Clin Cancer Res. 2015;21:3740–3749.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–2068.
   PubMed Web of Science ®Google Scholar
• Choi J, Cooper ML, Alahmari B, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.
   PubMed Web of Science ®Google Scholar
• Betts BC, Abdel-Wahab O, Curran SA, et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen. Blood. 2011;118:5330–5339.
   PubMed Web of Science ®Google Scholar
• Spoerl S, Mathew NR, Bscheider M, et al. Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. Blood. 2014;123:3832–3842.
   PubMed Web of Science ®Google Scholar
• Thomas SJ, Snowden JA, Zeidler MP, et al. The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015;113:365–371.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene. 2013;32:2601–2613.
   PubMed Web of Science ®Google Scholar
• Jones AV, Chase A, Silver RT, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41:446–449.
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Skoda RC, Looser R, et al. The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia. 2009;23:1924–1926.
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Harutyunyan A, Jäger R, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41:450–454.
   PubMed Web of Science ®Google Scholar
• Kilpivaara O, Mukherjee S, Schram AM, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41:455–459.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Patnaik MM, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24:105–109.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Chen B, Feng J, et al. The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leuk Lymphoma. 2010;51:1115–1120.
   PubMed Web of Science ®Google Scholar
• Andrikovics H, Nahajevszky S, Koszarska M, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24:1809–1813.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Lasho TL, Finke CM, et al. The JAK2 46/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients. Leukemia. 2010;24:110–114.
   PubMed Web of Science ®Google Scholar
• Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115:4517–4523.
   PubMed Web of Science ®Google Scholar
• Nahajevszky S, Andrikovics H, Batai A, et al. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica. 2011;96:1613–1618.
   PubMed Web of Science ®Google Scholar
• Kaklamani V. Can novel genetic polymorphisms predict response to therapy in acute myeloid leukemia? Leuk Lymphoma. 2010;51:1161–1162.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Daver N, Kantarjian HM, et al. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013;19:327–335.
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Kojima S, Furihata M, et al. Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. Int J Cancer. 2011;129:2512–2521.
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012;119:3219–3225.
   PubMed Web of Science ®Google Scholar
• Hermouet S, Vilaine M. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection? Haematologica. 2011;96:1575–1579.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–828.
   PubMed Web of Science ®Google Scholar
• Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139–170.
   PubMed Web of Science ®Google Scholar
• Petersdorf EW. Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev. 2013;27:1–12.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Kashiwase K, Matsuo K, et al. Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. Blood. 2015;125:1189–1197.
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Norden J. Non-HLA genomics: does it have a role in predicting haematopoietic stem cell transplantation outcome? Int J Immunogenet. 2015;42:229–238.
   PubMed Web of Science ®Google Scholar
• Kim D, Won HH, Su S, et al. Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models. Bone Marrow Transplant. 2014;49:649–656.
   PubMed Web of Science ®Google Scholar
• Chien JW, Zhang XC, Fan W, et al. Evaluation of published single nucleotide polymorphisms associated with acute GVHD. Blood. 2012;119:5311–5319.
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Charron D. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol. 2005;17:517–525.
   PubMed Web of Science ®Google Scholar
• Dickinson AM. Risk assessment in haematopoietic stem cell transplantation: pre-transplant patient and donor factors: non-HLA genetics. Best Pract Res Clin Haematol. 2007;20:189–207.
   PubMed Web of Science ®Google Scholar
• Ball LM, Egeler RM, Party EPW. Acute GvHD: pathogenesis and classification. Bone Marrow Transplant. 2008;41:S58–S64.
   PubMed Web of Science ®Google Scholar
• Hansen JA, Chien JW, Warren EH, et al. Defining genetic risk for graft-versus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol. 2010;17:483–492.
   PubMed Web of Science ®Google Scholar
• Takami A. Role of non-HLA gene polymorphisms in graft-versus-host disease. Int J Hematol. 2013;98:309–318.
   PubMed Web of Science ®Google Scholar
• Choi SW, Kitko CL, Braun T, et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood. 2008;112:1539–1542.
   PubMed Web of Science ®Google Scholar
• Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273–278.
   PubMed Web of Science ®Google Scholar
• Levine JE, Logan BR, Wu J, et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a blood and marrow transplant clinical trials network study. Blood. 2012;119:3854–3860.
   PubMed Web of Science ®Google Scholar
• Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicenter study. Lancet Haematol. 2015;2:e21–e29.
   PubMed Web of Science ®Google Scholar
• Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol. 2015;194:4604–4612.
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet. 2008;40:955–962.
   PubMed Web of Science ®Google Scholar
• Zhang JX, Song J, Wang J, et al. JAK2 rs10758669 polymorphisms and susceptibility to ulcerative colitis and Crohn’s disease: a meta-analysis. Inflammation. 2014;37:793–800.
   PubMed Web of Science ®Google Scholar
• Choi J, Ziga ED, Ritchey J, et al. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093–4103.
   PubMed Web of Science ®Google Scholar